Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study

被引:1
|
作者
Mponda, Marriam [1 ]
Kudowa, Evaristar [1 ]
Craven, Dalton M. [1 ]
Eastburg, Luke C. [1 ,2 ]
Chikasema, Maria [1 ]
Kasonkanji, Edwards [1 ]
Tomoka, Tamiwe [1 ,2 ]
Roush, Sophie Maharry [2 ]
Simwinga, Lusayo [1 ]
Mumba, Noel [1 ]
Gopal, Satish [3 ]
Fedoriw, Yuri [1 ,4 ]
Painschab, Matthew S. [1 ,2 ,4 ,5 ]
机构
[1] Univ N Carolina, Project Malawi, Lilongwe, Malawi
[2] Univ North Carolina Chapel Hill, Dept Med, Chapel Hill, NC USA
[3] NCI, Ctr Global Hlth, Rockville, MD USA
[4] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[5] UNC, Tidziwe Ctr, Project Lilongwe, Private Bag A-104, Lilongwe, Malawi
基金
美国国家卫生研究院;
关键词
Hodgkin lymphoma; HIV; ABVD; Sub-Saharan Africa; Cost; Microcosting; B-CELL LYMPHOMA; CANCER; CHEMOTHERAPY; OUTCOMES; THERAPY;
D O I
10.1016/j.eclinm.2024.102480
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background ABVD (doxorubicin, bleomycin, vinblastine, and dexamethasone) is a proven, curative regimen for Hodgkin lymphoma (HL). Prospective data describing HL treatment in sub-Saharan Africa are limited. We aimed to fill this knowledge gap, using data from Malawi. Methods We report a prospective observational cohort of HL (aged >= 15) from a single, tertiary referral centre in Malawi. We enrolled patients with pathologicially confirmed Hodgkin lymphoma between June 1, 2013, and Dec 31, 2021 with follow-up censored on May 31, 2022. Patients were treated with ABVD and concurrent antiretroviral therapy if HIV -positive and were followed up for 5 years. The primary outcome was overall survival; secondary outcomes included progression-free survival, response assessment, and adverse events. Microcosting of HL diagnosis, treatment, and follow-up was embedded. Findings We enrolled 38 patients with a median age of 27 years (interquartile range 19-46); eleven (28%) were HIV -positive. Of 35 patients treated with ABVD, 24 (71%) had stage III/IV, nine (26%) unfavourable limited stage, and two (6%) favourable limited stage. Among HIV-infected individuals, mean CD4 count at HL diagnosis was 179 cells/uL and ten (91%) had HIV RNA < 400 copies/mL. Grade 3/4 neutropenia occurred in 24 (68%) patients and caused treatment delay in 16 (46%). Of ten deaths, seven were due to HL, two possible treatment-related toxicity, and one uncertain. 2 -year overall survival was 82% (95% CI 70-96%) and 2 -year progression-free survival was 64% (95% CI 50-83%). PFS appeared better for HIV -positive patients (HR 0.23 (95% CI 0.05-1.02)) after controlling for stage and performance status (p = 0.05). We estimated $2708 (2022 USD) for HL diagnosis, treatment, and follow-up in our cohort. Interpretation Our findings suggest that treatment with ABVD is safe, efficacious, and affordable for HL in Malawi. Outcomes are worse than in high-income countries due to HL progression. Future studies are needed to understand outcome inequities and to assess efficacy of therapies for patients with relapsed or refractory HL in Malawi. Funding National Institutes of Health, Lineberger Comprehensive Cancer Center. Copyright (c) 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
    Chen, Robert
    Zinzani, Pier Luigi
    Fanale, Michelle A.
    Armand, Philippe
    Johnson, Nathalie A.
    Brice, Pauline
    Radford, John
    Ribrag, Vincent
    Molin, Daniel
    Vassilakopoulos, Theodoros P.
    Tomita, Akihiro
    von Tresckow, Bastian
    Shipp, Margaret A.
    Zhang, Yinghua
    Ricart, Alejandro D.
    Balakumaran, Arun
    Moskowitz, Craig H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2125 - +
  • [22] Balancing Efficacy and Safety in the Treatment of Adolescents With Hodgkin's Lymphoma
    Metzger, Monika L.
    Hudson, Melissa M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : 6071 - 6073
  • [23] Is classical Hodgkin lymphoma a different disease in the elderly? A single-ycenter retrospective cohort study
    Yildiz, J.
    Ulu, B. U.
    Yigenoglu, T. N.
    Basci, S.
    Darcin, T.
    Bakirtas, M.
    Sahin, D.
    Batgi, H.
    Merdin, A.
    Baysal, N. A.
    Iskender, D.
    Cakar, M. K.
    Dal, M. S.
    Altuntas, F.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (10) : 3655 - 3660
  • [24] Real-world treatment outcomes for Hodgkin lymphoma in South Africa: a prospective observational study
    Vogt, Samantha L.
    Laudin, Garrick
    Zahurak, Marianna
    Vaughan, Jenifer
    Lakha, Atul
    Pather, Sugeshnee
    Waja, Ziyaad
    Chetty, Deshan
    Omar, Tanvier
    Stevens, Wendy
    Ashmore, Philippa
    Otwombe, Kennedy
    Hlongwane, Khuthadzo
    Varadhan, Ravi
    Patel, Moosa
    Ambinder, Richard F.
    Martinson, Neil A.
    Xian, Rena R.
    Philip, Vinitha
    INFECTIOUS AGENTS AND CANCER, 2024, 19 (01):
  • [25] Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
    Younes, Anas
    Oki, Yasuhiro
    McLaughlin, Peter
    Copeland, Amanda R.
    Goy, Andre
    Pro, Barbara
    Feng, Lei
    Yuan, Ying
    Chuang, Hubert H.
    Macapinlac, Homer A.
    Hagemeister, Fredrick
    Romaguera, Jorge
    Samaniego, Felipe
    Fanale, Michelle A.
    Dabaja, Bouthaina Shbib
    Rodriguez, Maria A.
    Dang, Nam
    Kwak, Larry W.
    Neelapu, Sattva S.
    Fayad, Luis E.
    BLOOD, 2012, 119 (18) : 4123 - 4128
  • [26] Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
    Janku, Filip
    Park, Haeseong
    Call, S. Greg
    Madwani, Kiran
    Oki, Yasuhiro
    Subbiah, Vivek
    Hong, David S.
    Naing, Aung
    Velez-Bravo, Vivianne M.
    Barnes, Tamara G.
    Hagemeister, Fredrick B.
    Falchook, Gerald S.
    Karp, Daniel D.
    Wheler, Jennifer J.
    Piha-Paul, Sarina A.
    Garrido-Laguna, Ignacio
    Shpall, Elizabeth J.
    Fayad, Luis E.
    Neelapu, Sattva S.
    Meric-Bernstam, Funda
    Kurzrock, Razelle
    Fanale, Michelle A.
    CLINICAL CANCER RESEARCH, 2020, 26 (21) : 5579 - 5587
  • [27] Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial
    Kimani, Stephen
    Painschab, Matthew S.
    Kaimila, Bongani
    Kasonkanji, Edwards
    Zuze, Takondwa
    Tomoka, Tamiwe
    Mulenga, Maurice
    Nyasosela, Richard
    Chikasema, Maria
    Mtangwanika, Asekanadziwa
    Chawinga, Mena
    Mhango, Wilberforce
    Nicholas, Simon
    Chimzimu, Fred
    Kampani, Coxcilly
    Krysiak, Robert
    Lilly, Amy
    Randall, Cara
    Seguin, Ryan
    Westmoreland, Katherine D.
    Montgomery, Nathan D.
    Fedoriw, Yuri
    Gopal, Satish
    LANCET GLOBAL HEALTH, 2021, 9 (07): : E1008 - E1016
  • [28] A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
    Lepik, Kirill V.
    Mikhailova, Natalia B.
    Kondakova, Elena V.
    Zalyalov, Yuri R.
    Fedorova, Liudmila V.
    Tsvetkova, Luibov A.
    Kotselyabina, Polina V.
    Borzenkova, Evgeniya S.
    Babenko, Elena V.
    Popova, Marina O.
    Darskaya, Elena I.
    Baykov, Vadim V.
    Moiseev, Ivan S.
    Afanasyev, Boris V.
    HEMASPHERE, 2020, 4 (03):
  • [29] Efficacy and Safety of First Line Vincristine with Doxorubicin, Bleomycin and Dacarbazine (ABOD) for Hodgkin's Lymphoma: a Single Institute Experience
    Ozdemir, Nuriye
    Dogan, Mutlu
    Sendur, Mehmet Ali Nahit
    Yazici, Ozan
    Abali, Huseyin
    Yazilitas, Dogan
    Akinci, Muhammed Bulent
    Aksoy, Sercan
    Zengin, Nurullah
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (20) : 8715 - 8718
  • [30] Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials
    Borchmann, S.
    Mueller, H.
    Hude, I
    Fuchs, M.
    Borchmann, P.
    Engert, A.
    ANNALS OF ONCOLOGY, 2019, 30 (08) : 1329 - 1334